Logo image of ATOS

ATOSSA THERAPEUTICS INC (ATOS) Stock Fundamental Analysis

NASDAQ:ATOS - Nasdaq - US04962H5063 - Common Stock - Currency: USD

0.8305  -0.03 (-3.43%)

After market: 0.8212 -0.01 (-1.12%)

Fundamental Rating

3

Taking everything into account, ATOS scores 3 out of 10 in our fundamental rating. ATOS was compared to 559 industry peers in the Biotechnology industry. While ATOS has a great health rating, there are worries on its profitability. ATOS is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

ATOS had negative earnings in the past year.
In the past year ATOS has reported a negative cash flow from operations.
In the past 5 years ATOS always reported negative net income.
In the past 5 years ATOS always reported negative operating cash flow.
ATOS Yearly Net Income VS EBIT VS OCF VS FCFATOS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -10M -20M -30M

1.2 Ratios

Looking at the Return On Assets, with a value of -37.24%, ATOS is in line with its industry, outperforming 59.57% of the companies in the same industry.
With a decent Return On Equity value of -40.33%, ATOS is doing good in the industry, outperforming 70.48% of the companies in the same industry.
Industry RankSector Rank
ROA -37.24%
ROE -40.33%
ROIC N/A
ROA(3y)-28.82%
ROA(5y)-30.64%
ROE(3y)-30.53%
ROE(5y)-37.72%
ROIC(3y)N/A
ROIC(5y)N/A
ATOS Yearly ROA, ROE, ROICATOS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -100 -200 -300 -400

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for ATOS so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ATOS Yearly Profit, Operating, Gross MarginsATOS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024

More info and screens

8

2. Health

2.1 Basic Checks

ATOS has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, ATOS has more shares outstanding
There is no outstanding debt for ATOS. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
ATOS Yearly Shares OutstandingATOS Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M
ATOS Yearly Total Debt VS Total AssetsATOS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M

2.2 Solvency

An Altman-Z score of 7.73 indicates that ATOS is not in any danger for bankruptcy at the moment.
ATOS has a better Altman-Z score (7.73) than 83.36% of its industry peers.
There is no outstanding debt for ATOS. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 7.73
ROIC/WACCN/A
WACCN/A
ATOS Yearly LT Debt VS Equity VS FCFATOS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M 100M

2.3 Liquidity

ATOS has a Current Ratio of 12.67. This indicates that ATOS is financially healthy and has no problem in meeting its short term obligations.
ATOS has a better Current ratio (12.67) than 84.44% of its industry peers.
ATOS has a Quick Ratio of 12.67. This indicates that ATOS is financially healthy and has no problem in meeting its short term obligations.
ATOS has a better Quick ratio (12.67) than 84.44% of its industry peers.
Industry RankSector Rank
Current Ratio 12.67
Quick Ratio 12.67
ATOS Yearly Current Assets VS Current LiabilitesATOS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M

More info and screens

1

3. Growth

3.1 Past

ATOS shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 22.22%, which is quite impressive.
EPS 1Y (TTM)22.22%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%0%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

ATOS is expected to show a small growth in Earnings Per Share. In the coming years, the EPS will grow by 4.11% yearly.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-21.43%
EPS Next 2Y-15.22%
EPS Next 3Y-10.13%
EPS Next 5Y4.11%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
ATOS Yearly Revenue VS EstimatesATOS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2028 2029 2030 2031 2032 200M 400M 600M 800M
ATOS Yearly EPS VS EstimatesATOS Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 -20 -40 -60 -80

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for ATOS. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ATOS. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ATOS Price Earnings VS Forward Price EarningsATOS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ATOS Per share dataATOS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.2 -0.2 0.4

4.3 Compensation for Growth

ATOS's earnings are expected to decrease with -10.13% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-15.22%
EPS Next 3Y-10.13%

More info and screens

0

5. Dividend

5.1 Amount

ATOS does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ATOSSA THERAPEUTICS INC

NASDAQ:ATOS (6/13/2025, 8:00:01 PM)

After market: 0.8212 -0.01 (-1.12%)

0.8305

-0.03 (-3.43%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-13 2025-05-13/bmo
Earnings (Next)08-11 2025-08-11
Inst Owners26.58%
Inst Owner Change-6.38%
Ins Owners0.04%
Ins Owner Change35.87%
Market Cap107.28M
Analysts82.22
Price Target6.2 (646.54%)
Short Float %5.53%
Short Ratio9.91
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)18.05%
Min EPS beat(2)13.5%
Max EPS beat(2)22.6%
EPS beat(4)3
Avg EPS beat(4)11.45%
Min EPS beat(4)-3.8%
Max EPS beat(4)22.6%
EPS beat(8)5
Avg EPS beat(8)1.98%
EPS beat(12)9
Avg EPS beat(12)4.7%
EPS beat(16)12
Avg EPS beat(16)2.22%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)1.39%
PT rev (3m)1.39%
EPS NQ rev (1m)0%
EPS NQ rev (3m)7.69%
EPS NY rev (1m)1.96%
EPS NY rev (3m)7.41%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 1.64
P/tB 1.64
EV/EBITDA N/A
EPS(TTM)-0.21
EYN/A
EPS(NY)-0.28
Fwd EYN/A
FCF(TTM)-0.17
FCFYN/A
OCF(TTM)-0.17
OCFYN/A
SpS0
BVpS0.51
TBVpS0.51
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -37.24%
ROE -40.33%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-28.82%
ROA(5y)-30.64%
ROE(3y)-30.53%
ROE(5y)-37.72%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 137.5%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 12.67
Quick Ratio 12.67
Altman-Z 7.73
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)157.54%
Cap/Depr(5y)108.53%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)22.22%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%0%
EPS Next Y-21.43%
EPS Next 2Y-15.22%
EPS Next 3Y-10.13%
EPS Next 5Y4.11%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y10.25%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y2.65%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y2.66%
OCF growth 3YN/A
OCF growth 5YN/A